Osteopontin as Candidate Biomarker of Coronary Disease despite Low Cardiovascular Risk: Insights from CAPIRE Study

Carbone, Federico; Meessen, Jennifer; Magnoni, Marco; Andreini, Daniele; Maggioni, Aldo P.; Latini, Roberto; Montecucco, Fabrizio

doi:10.3390/cells11040669

Cited by 6 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to existing evidence linking OPN/microcalcification to 18 F-sodium fluoride uptake in coronary arteries [24], OPN has been gaining more interest as a biomarker for increased risk of myocardial infarction (MI) in asymptomatic patients, as well as its role as a predictor of adverse outcomes in patients with carotid stenosis [38][39][40][41][42]. Limited work has been conducted in patients undergoing CABG, with one study showing decreased levels 72 h after surgery [43]; however, the authors did not study level changes at later time points considering evidence that OPN is detected at later times after injury [44].…”

Section: Discussionmentioning

confidence: 99%

Osteopontin Activation and Microcalcification in Venous Grafts Can Be Modulated by Dexamethasone

McQueen,

Ladak,

Layton

et al. 2023

Cells

View full text Add to dashboard Cite

Background: Osteopontin has been implicated in vascular calcification formation and vein graft intimal hyperplasia, and its expression can be triggered by pro-inflammatory activation of cells. The role of osteopontin and the temporal formation of microcalcification in vein grafts is poorly understood with a lack of understanding of the interaction between haemodynamic changes and the activation of osteopontin. Methods: We used a porcine model of vein interposition grafts, and human long saphenous veins exposed to ex vivo perfusion, to study the activation of osteopontin using polymerase chain reaction, immunostaining, and 18F-sodium fluoride autoradiography. Results: The porcine model showed that osteopontin is active in grafts within 1 week following surgery and demonstrated the presence of microcalcification. A brief pretreatment of long saphenous veins with dexamethasone can suppress osteopontin activation. Prolonged culture of veins after exposure to acute arterial haemodynamics resulted in the formation of microcalcification but this was suppressed by pretreatment with dexamethasone. 18F-sodium fluoride uptake was significantly increased as early as 1 week in both models, and the pretreatment of long saphenous veins with dexamethasone was able to abolish its uptake. Conclusions: Osteopontin is activated in vein grafts and is associated with microcalcification formation. A brief pretreatment of veins ex vivo with dexamethasone can suppress its activation and associated microcalcification.

show abstract

Section: Discussionmentioning

confidence: 99%

Osteopontin Activation and Microcalcification in Venous Grafts Can Be Modulated by Dexamethasone

McQueen,

Ladak,

Layton

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“…Notably, OPN levels tended to decrease in individuals after undergoing coronary artery graft bypass (CABG) surgery, indicating the close association between OPN and coronary patency [50]. In patients with established CAD, the relationship between OPN and CAD presence is inconsistent, and co-existing cardiovascular risk factors may be significant confounders, limiting its clinical impact [51,52].…”

Section: Opn and Presence Of Coronary Artery Diseasementioning

confidence: 99%

The Role of Osteopontin in Atherosclerosis and Its Clinical Manifestations (Atherosclerotic Cardiovascular Diseases)—A Narrative Review

Kadoglou,

Khattab,

Velidakis

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Atherosclerotic cardiovascular diseases (ASCVDs) are the most common and severe public health problem nowadays. Osteopontin (OPN) is a multifunctional glycoprotein highly expressed at atherosclerotic plaque, which has emerged as a potential biomarker of ASCVDs. OPN may act as an inflammatory mediator and/or a vascular calcification (VC) mediator, contributing to atherosclerosis progression and eventual plaque destabilization. In this article, we discuss the complex role of OPN in ASCVD pathophysiology, since many in vitro and in vivo experimental data indicate that OPN contributes to macrophage activation and differentiation, monocyte infiltration, vascular smooth muscle cell (VSMC) migration and proliferation and lipid core formation within atherosclerotic plaques. Most but not all studies reported that OPN may inhibit atherosclerotic plaque calcification, making it “vulnerable”. Regarding clinical evidence, serum OPN levels may become a biomarker of coronary artery disease (CAD) presence and severity. Significantly higher OPN levels have been found in patients with acute coronary syndromes than those with stable CAD. In limited studies of patients with peripheral artery disease, circulating OPN concentrations may be predictive of future major adverse cardiovascular events. Overall, the current literature search suggests the contribution of OPN to atherosclerosis development and progression, but more robust evidence is required.

show abstract

“…Определены следующие тенденции: прямые слабые корреляционные взаимосвязи уровня остеопонтина с индексом BODE, значением шкалы CAT, шкалы mMRC как в группе ХОБЛ и ИБС, так и в группе ХОБЛ без ИБС (взаимосвязи были статистически не значимы, необходим более значительный объем выборки). [20]. Для оценки связи остеопонтина с риском сердечно-сосудистых событий у пациентов с ХОБЛ необходимо дальнейшее изучение возможной взаимосвязи уровня остеопонтина с изменениями в липидном профиле и функциональной активностью тромбоцитов.…”

Section: результатыunclassified

Osteopontin in patients with chronic obstructive pulmonary disease and coronary heart disease

Suvorova

Гордеев

Лучинкина

2023

Almanac of Clinical Medicine

View full text Add to dashboard Cite

Background: Osteopontin is a protein expressed by various cell types, such as endothelial and epithelial cells, osteoclasts, hepatocytes, smooth muscle cells, activated macrophages, and T-cells. Cardiomyocytes, heart fibroblasts, endothelial cells of coronary arteries express osteopontin in response to hypoxia, inflammation, toxic factors, mechanical strain, and other stimuli. Aim: To study osteopontin levels in patients with chronic obstructive pulmonary disease (COPD) depending on concomitant ischemic heart disease (IHD), to identify an association between osteopontin levels with severity of COPD and functional lung test parameters. Materials and methods: This open-label, prospective, non-randomized comparative study with parallel groups included 99 patients with COPD grades AD by GOLD, with 49 of them having confirmed comorbid stable IHD. Serum osteopontin levels were measured by immunoenzyme assay (Human Osteopontin Platinum ELISA; Bender MedSystems, Austria). The data is given as medians and quartiles (Me [Q1; Q3]). In all patients we performed functional lung tests with bronchodilation, a 6-minute walking test, BODE index assessment, as well as CAT and mMRC questionnaires were used. Results: In the patients with COPD and IHD, the osteopontin levels were higher than in the patients with COPD without IHD (85.55 [46.86; 110.91] vs 55.43 [20.76; 89.64] ng/mL, respectively; p = 0.027). Osteopontin levels in the patients with all COPD grades and IHD were higher than in those without IHD, but the difference was significant only in GOLD grade B patients (91.28 [73.04; 110.91] vs 37.81 [22.54; 82.95] ng/mL, respectively, р = 0.028) and GOLD grade D patients (80.79 [34.65; 111.11] vs 37.46 [13.32; 109.5] ng/mL, respectively, р = 0.027). Conclusion: A significant increase of osteopontin levels in comorbid patients with COPD and stable IHD found in this study has not been previously known. It is necessary to perform further studies to identify a threshold level of osteopontin predictive of the risk of COPD exacerbations or cardiovascular events. This would help to improve medical treatment of COPD patients, as well as to identify the risk groups.

show abstract

Osteopontin as Candidate Biomarker of Coronary Disease despite Low Cardiovascular Risk: Insights from CAPIRE Study

Cited by 6 publications

References 46 publications

Osteopontin Activation and Microcalcification in Venous Grafts Can Be Modulated by Dexamethasone

Osteopontin Activation and Microcalcification in Venous Grafts Can Be Modulated by Dexamethasone

The Role of Osteopontin in Atherosclerosis and Its Clinical Manifestations (Atherosclerotic Cardiovascular Diseases)—A Narrative Review

Osteopontin in patients with chronic obstructive pulmonary disease and coronary heart disease

Contact Info

Product

Resources

About